ETON Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. (ETON) is expected to report earnings on November 12, 2026, after the market close. The consensus earnings estimate is $0.16 per share, and the stock has had a Post-Earnings Announcement Drift (PEAD) of +7.2% since its last earnings release on August 13, 2026.
Sign in or subscribe to unlock sentiment, short interest, and technical indicators.
Whisperings™
About Eton Pharmaceuticals, Inc.
Eton Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on developing and commercializing innovative treatments for rare pediatric diseases. The company currently owns or receives royalties from three FDA-approved products, including ALKINDI® SPRINKLE, Biorphen®, and Alaway Preservative Free®, and has six additional products that have been submitted to the FDA.
Sector
Healthcare
Industry
Biotechnology